The national medical insurance catalog has included nearly one hundred kinds of drugs for rare diseases, covering 42 types of diseases.

From September 19th to 21st, the 7th China Rare Disease Conference jointly organized by the National Rare Disease Diagnosis and Treatment Collaboration Network Office, the China Rare Disease Alliance, the Rare Disease Branch of the Chinese Medical Association, and more than 30 institutions across the country was held in Beijing. It was revealed at the conference that by 2025, various aspects of the rare disease field have been steadily developing, with 21 rare disease drugs approved for market in the first half of the year. The upcoming national commercial health insurance innovative drug list will further improve the multi-level protection system for rare diseases. Huang Xinyu, Director of the Medical Service Management Department of the National Medical Security Administration, stated that a triple protection system has been established, consisting of basic medical insurance, major disease insurance, and medical assistance. There are approximately 100 rare disease drugs in the national medical insurance catalog, covering 42 types of rare diseases. In 2024, the medical insurance fund will pay 8.6 billion for rare disease drugs during the agreement period, accounting for about 7.7% of the total drug payment during the agreement period. The National Medical Insurance Administration is actively promoting the entry of drugs from the medical insurance catalog into hospitals and the construction of a "dual-channel" drug supply mechanism to ensure accessibility to medication. Huang Xinyu pointed out that the commercial health insurance fund in China has reached 977.3 billion in 2024 and can form a comprehensive protection system that complements the national basic medical insurance.